CSI Market
Sign In | Register

Taro Pharmaceutical Industries Ltd (TARO) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access TARO Annual Income Statement →
Income statement data covering Taro Pharmaceutical Industries Ltd–Mar 31 2022 offers a view into how Mar 31 2023's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
Q4 2023 		0 0 0 (Mar 31 2022)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax572.95
Total Revenue572.95
Costs & Expenses
Cost of Goods and Services Sold304.63
Gross Profit268.32
Selling, Administration, Marketing198.37
Research and Development Expense52.24
(Gain) Loss Related to Litigation Settlement0.00
Other Operating Expense / -Income0.00
Total operating costs including COS555.24
Operating income / -loss17.71
Net Interest Expense / -Income0.00
Nonoperating Gains (Losses)0.00
Other loss / -income-20.50
Total costs & expenses534.74
Income & Taxes
Income / -loss before income taxes38.21
Income taxes expenses / -benefit12.77
Income after income taxes25.45
Net income / -loss of other equity0.00
Income / -loss from continuing operations25.45
Net income / -loss25.45
Income / -loss to shareholder25.45
EBIT38.21
EBITD70.34
EBITDA70.34
Earnings Per Share
Basic EPS (excl. extra items)0.68
Basic Net EPS0.68
Basic shares outstanding (Mill. of Units)37.59
Diluted Net EPS0.68
Diluted average shares (Mill. of Units)37.59
4 historic quarters locked

Sign in to unlock the full Taro Pharmaceutical Industries Ltd income statement history.

Sign In Create Free Account

About TARO Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.